7/24/2013

Chemotherapy combined with Roche Holding's investigational drug obinutuzumab slowed the progression of chronic lymphocytic leukemia better than rituximab in a late-stage trial. Obinutuzumab is a monoclonal antibody that stimulate a patient's immune system to fight cancer cells.

Full Story:
Reuters

Related Summaries